See the DrugPatentWatch profile for dasatinib
What is US6596746B1 (and how does it relate to dasatinib)?
US6596746B1 is a patent that appears in Google Patents under that document number, and it is commonly searched alongside “dasatinib” because it sits in the same broader area of small-molecule kinase inhibitors. Dasatinib itself is a specific marketed kinase inhibitor, so users often look for US patents from around the same therapeutic space to understand the underlying chemistry, targets, or earlier priority disclosures.
If you tell me what you want to know (for example, “the claims,” “the assignee,” “the invention summary,” or “whether it covers dasatinib”), I can map the patent’s key details directly to dasatinib’s structure/target and explain how it is being used in searches.
What details should I check on Google Patents to see the connection to dasatinib?
On Google Patents, the quickest way to determine whether US6596746B1 is actually relevant to dasatinib is to compare these fields:
- Assignee/applicant: dasatinib-related filings often list the research company responsible for the drug candidate and its core kinase-inhibitor series.
- Priority date(s): a patent that predates dasatinib’s key development milestones can still be relevant if it discloses related inhibitor scaffolds.
- Claim language: if the claims explicitly cover a compound of the same general formula or a specific example matching dasatinib, that is a stronger link than general discussion of kinase inhibition.
- Examples and compound tables: dasatinib’s chemical name or structure identifiers (or close analogs) in the examples are strong evidence of direct overlap.
- Target/kinase description: dasatinib is a multi-kinase inhibitor used in certain cancers; patents that focus on the same kinase target(s) (or closely related family members) are more likely to be searched together.
Could US6596746B1 cover dasatinib, or is it more likely prior art?
A frequent reason people search a specific patent number with a drug name is either:
- direct coverage (the claims read on dasatinib or its close analogs), or
- prior art context (the patent discloses related chemical matter or methods, which can be used to argue obviousness, enablement, or novelty).
Without the patent text you’re looking at (claims/exemplified compounds), I can’t say which of those is true for US6596746B1.
What are you trying to do with this patent link?
Different goals lead to different answers:
- If you’re doing freedom-to-operate (FTO) research, we’d look at claim scope, jurisdiction, expiration, and whether there are later improvements or separate patents on formulation/manufacturing.
- If you’re doing invalidity/prior-art research, we’d focus on whether US6596746B1 discloses dasatinib’s key structural features and whether it teaches the same use/target.
- If you’re doing academic/technology tracing, we’d focus on how the disclosed inhibitor class relates to dasatinib’s mechanism and chemical scaffold.
If you paste one line from the Google Patents page, I can answer precisely
If you paste any of the following from the Google Patents page for US6596746B1, I’ll interpret it in relation to dasatinib:
- the assignee/applicant name
- the abstract
- one independent claim
- the “Examples” entry that lists compounds (or the chemical name of the example)
Sources: none provided (you asked about a specific patent number, but no Google Patents content or excerpts were included).